New Appointment: Psilera, Inc. has appointed Scott W. Rairigh as Executive Vice President of Corporate Development to enhance its business and commercialization strategies for neurological therapies.
Rairigh's Background: Rairigh brings extensive experience from Celgene, Bristol Myers Squibb, and Johnson & Johnson, focusing on personalized medicine in oncology, hematology, and neuroscience, particularly in brain health.
BMY
$54.23+Infinity%1D
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 52.67 USD with a low forecast of 36.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast BMY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 52.67 USD with a low forecast of 36.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
11 Hold
1 Sell
Moderate Buy
Current: 54.290
Low
36.00
Averages
52.67
High
68.00
Current: 54.290
Low
36.00
Averages
52.67
High
68.00
Goldman Sachs
Neutral
maintain
$51 -> $57
2025-12-15
New
Reason
Goldman Sachs
Price Target
$51 -> $57
2025-12-15
New
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Bristol Myers to $57 from $51 and keeps a Neutral rating on the shares.
BofA
Neutral -> Buy
upgrade
$52 -> $61
2025-12-15
New
Reason
BofA
Price Target
$52 -> $61
2025-12-15
New
upgrade
Neutral -> Buy
Reason
BofA upgraded Bristol Myers to Buy from Neutral with a price target of $61, up from $52.
BofA
Neutral -> Buy
upgrade
$52 -> $61
2025-12-15
New
Reason
BofA
Price Target
$52 -> $61
2025-12-15
New
upgrade
Neutral -> Buy
Reason
As previously reported, BofA upgraded Bristol Myers to Buy from Neutral with a price target of $61, up from $52, based on the strength of Bristol's R&D pipeline. The firm expects 4-6 programs to deliver key de-risking catalysts in the near-term and sees current weakness as a buying opportunity as conservative trough EPS provides a floor for share price and "good pharma pipeline stories can work once investors have visibility on the next product cycle," the analyst contends ahead of "a catalyst-rich 2026." The firm sees multiple scenarios that could position the company for return to growth in 2029 and beyond, the analyst added.
Guggenheim
Neutral -> Buy
upgrade
$62
2025-12-12
New
Reason
Guggenheim
Price Target
$62
2025-12-12
New
upgrade
Neutral -> Buy
Reason
As previously reported, Guggenheim upgraded Bristol Myers to Buy from Neutral with a $62 price target ahead of 2026, which the firm believes "offers a much more compelling value-oriented and pipeline-driven risk/reward." Given already low expectations for earnings and clinical readouts, the firm views the stock's 2026 floor to be "closer to $50/shr," the analyst tells investors. Meanwhile, recent developments together with ongoing deep dive work into FXI/a, LPA1 and sotatercept sales "offers an attractive (perhaps even compelling entry point) for yield-oriented value investors," the analyst argues.
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
